ImmunoPrecise Antibodies Ltd. - SIC # 8010 -

Ticker Exchange SIC # Website Latest Ticker
IPA Nasdaq 8010 www.ipatherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ImmunoPrecise Antibodies Ltd.

IPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference - Dec 4th, 2024 1:00 pm
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024 - Dec 3rd, 2024 1:30 pm
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 - Nov 27th, 2024 12:00 pm
$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies - Nov 13th, 2024 2:00 pm
ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation - Nov 4th, 2024 1:01 pm
ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology - Oct 28th, 2024 11:30 am
ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024 - Oct 21st, 2024 1:00 pm
ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design - Oct 10th, 2024 12:10 pm
ImmunoPrecise Antibodies Ltd (IPA) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amid ... - Oct 9th, 2024 7:21 pm
ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus - Oct 2nd, 2024 12:00 pm
ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments - Sep 26th, 2024 1:00 pm
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 - Sep 16th, 2024 1:00 pm
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024 - Sep 9th, 2024 1:11 pm
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York - Aug 26th, 2024 1:00 pm
ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements - Aug 24th, 2024 12:00 am
ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology - Aug 19th, 2024 1:00 pm
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024 - Jul 29th, 2024 12:30 pm
ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024 - Jul 23rd, 2024 11:30 pm
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures - Jul 17th, 2024 12:01 am
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024 - Jul 15th, 2024 12:31 pm